Strides Shasun gets DCGI nod to manufacture Hepatitis C drug

Published On 2015-12-22 06:38 GMT   |   Update On 2015-12-22 06:38 GMT
Advertisement

New Delhi: Drug firm Strides Shasun has received approval from the Drug Controller General of India (DCGI) to produce a generic version of Gilead's 'Sovaldi' used for treatment of Hepatitis C.



The company has received approval for manufacturing a generic version of Sofosbuvir 400 mg, Strides Shasun said in a filing to BSE.

Last year, Strides had entered into a licensing agreement with Gilead Sciences to bring Hepatitis C cure to 91 developing countries.
Advertisement

"The product will continue to be marketed under the brand name Virso in India and overseas," Strides Shasun said.

Sofosbuvir is the first-in-class polymerase inhibitor to be launched in India for Hepatitis C treatment and represents "a paradigm shift" in the existing Hepatitis C cure, it added.

"The high potency, high barrier to resistance and pan genotype activity make Sofosbuvir a breakthrough drug in Hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90 per cent," it said.

Globally, it is estimated that 170-185 million people are chronically infected with Hepatitis C virus. In India alone, it is estimated that 12-18 million patients are infected with the disease, which is several fold higher than those with HIV/AIDS.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News